BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30489430)

  • 21. Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor.
    Roncati L; Palmieri B
    Int J Dermatol; 2020 Jul; 59(7):763-769. PubMed ID: 32441324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
    Zhou J; Dudley ME; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive T-cell transfer in melanoma.
    Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
    Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.
    Krishna S; Lowery FJ; Copeland AR; Bahadiroglu E; Mukherjee R; Jia L; Anibal JT; Sachs A; Adebola SO; Gurusamy D; Yu Z; Hill V; Gartner JJ; Li YF; Parkhurst M; Paria B; Kvistborg P; Kelly MC; Goff SL; Altan-Bonnet G; Robbins PF; Rosenberg SA
    Science; 2020 Dec; 370(6522):1328-1334. PubMed ID: 33303615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.
    Pen JJ; De Keersmaecker B; Maenhout SK; Van Nuffel AM; Heirman C; Corthals J; Escors D; Bonehill A; Thielemans K; Breckpot K; Aerts JL
    J Immunol; 2013 Aug; 191(4):1976-83. PubMed ID: 23842750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.
    Bonehill A; Tuyaerts S; Van Nuffel AM; Heirman C; Bos TJ; Fostier K; Neyns B; Thielemans K
    Mol Ther; 2008 Jun; 16(6):1170-80. PubMed ID: 18431362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.
    Tang YY; Sheng SY; Lu CG; Zhang YQ; Zou JY; Lei YY; Gu Y; Hong H
    J Immunother; 2018 Sep; 41(7):319-328. PubMed ID: 29877972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.
    Idorn M; Thor Straten P; Svane IM; Met Ö
    Methods Mol Biol; 2016; 1428():261-76. PubMed ID: 27236805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
    Johnson LA; Heemskerk B; Powell DJ; Cohen CJ; Morgan RA; Dudley ME; Robbins PF; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6548-59. PubMed ID: 17056587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
    Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.
    Donia M; Hansen M; Sendrup SL; Iversen TZ; Ellebæk E; Andersen MH; Straten Pt; Svane IM
    J Invest Dermatol; 2013 Feb; 133(2):545-52. PubMed ID: 23014345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
    Zhou J; Shen X; Huang J; Hodes RJ; Rosenberg SA; Robbins PF
    J Immunol; 2005 Nov; 175(10):7046-52. PubMed ID: 16272366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.